NEW BRUNSWICK, N.J., March 16, 2011 /PRNewswire-USNewswire/ -- Working with the Foundation of UMDNJ and New Jersey Health Foundation, Rostock Biotech Research Ltd, headquartered in Moscow, Russia, has donated $100,000 to fund the research of Dr. Alexey G. Ryazanov, a professor in the Department of Pharmacology at UMDNJ-Robert Wood Johnson Medical School (RWJMS) and a member of The Cancer Institute of New Jersey.
The Blue Sky Research and Development Fund in Pharmacology in the Department of Pharmacology allows Dr. Ryazanov to investigate cellular and molecular mechanisms of aging and age-related diseases and to pursue research that would lead to better understanding of the fundamental principles of drug action.
"This funding permits Dr. Ryazanov to pursue cutting edge research without limitations on ideas or hypothesis," explained Dmitri Khan of Rostock Group, parent of Rostock Biotech Research. "We hope it will open the door for Dr. Ryazanov and his team to make unlimited discoveries that will have a positive impact in the future."
Working in concert with donors, the Foundation of UMDNJ/New Jersey Health Foundation can develop fund agreements that are individually tailored to meet donor needs.
"Because many of our donors wish to remain connected to the areas they help fund, this agreement, like many others we have developed, provides an opportunity for representatives from Rostock to meet with department representatives periodically to discuss innovative findings that might come about as a result of this research," explained George F. Heinrich, M.D., vice chair and CEO of the Foundation. "It's very exciting for a researcher to be able to share his or her results with others who are passionate about their work."
To learn more about how you can fund research in an area that means the most to you, contact James M. Golubieski, Foundation president, at (908) 731-6601 or firstname.lastname@example.org.
About the Foundation of UMDNJ
The Foundation of UMDNJ is an independent, not-for-profit organization that connects individuals, corporations and foundations that want to advance healthcare with those at UMDNJ who are pursuing those same passions. For more information, visit www.foundationofumdnj.org
About the Rostock Group
The Rostock Group, established in March 2009, is committed to developing projects that are significant for the society in general. Its mission is to improve future of the humankind, including extending the active lifespan, curing currently incurable diseases, creating an ecological and energy-efficient environment, and eliminating threats to the humankind. To learn more, visit www.grostock.com/en/.
The University of Medicine and Dentistry of New Jersey (UMDNJ) is the nation's largest free-standing public health sciences university with more than 6,000 students attending the state's three medical schools, its only dental school, a graduate school of biomedical sciences, a school of health related professions, a school of nursing and its only school of public health on five campuses. Annually, there are more than two million patient visits at UMDNJ facilities and faculty practices at campuses in Newark, New Brunswick/Piscataway, Scotch Plains, Camden and Stratford. UMDNJ operates University Hospital, a Level I Trauma Center in Newark, and University Behavioral HealthCare, which provides a continuum of healthcare services with multiple locations throughout the state. Visit www.umdnj.edu.
SOURCE New Jersey Health Foundation